Introduction: Adverse drug reactions are more common in geriatric patients than in younger patients, but there have been insufficient studies concerning the epidemiology or burden of drug allergy labels in geriatric patients. We prospectively investigated the prevalence and outcomes of geriatric patients with drug allergy labels in a cohort of hospitalised patients.

Methods: Patients admitted to a regional hospital over a 6-month period were recruited for this study. All patients with drug allergy labels were prospectively followed until discharge; clinical data were anonymously extracted for analyses. Patients were categorised into either geriatric (aged ≥65 years) or non-geriatric (aged <65 years) groups. Demographic characteristics, clinical outcomes, and prevalences of drug allergy labels were compared between groups.

Results: There were 4361 admissions involving 3641 patients during the 6-month study period. Overall, 492 patients (13.5%) had drug allergy labels, consisting of 151 non-geriatric patients (30.7%) and 341 geriatric patients (69.3%). The prevalence of drug allergy labels did not significantly differ between geriatric and non-geriatric patients (13.5% vs 13.5%, P=0.976). Significantly more patients in the geriatric group had drug allergy labels to cardiovascular system drugs (15.5% vs 4.6%, P=0.001). Geriatric patients had a significantly lower rate of direct discharge from the hospital (73.0% vs 88.1%, P<0.001) and required transfers to convalescent or rehabilitation care for further management.

Conclusions: More than 13% of hospitalised geriatric patients had drug allergy labels. The leading causes of drug allergy labels were similar between geriatric and non-geriatric patients. Geriatric patients with drug allergy labels had significantly more labelled allergies to cardiovascular system drugs and adverse clinical outcomes.

New knowledge added by this study
- More than 13% of hospitalised geriatric patients in Hong Kong had drug allergy (DA) labels.
- The most common DA labels were similar between geriatric and non-geriatric patients.
- Geriatric patients had significantly more DA labels to cardiovascular drugs and significantly lower direct discharge rates.

Implications for clinical practice or policy
- Clinicians should consider the large burden of reported DAs and associated adverse clinical outcomes among hospitalised geriatric patients, particularly with respect to antibiotic therapy and cardiovascular system drugs.
- Geriatric patients with reported DAs should be selectively referred for formal allergy workup to confirm or refute suspected DAs.

Introduction
With the continued increase in life expectancy worldwide, population ageing is an especially marked phenomenon in Asian populations. It has been estimated that nearly one in three individuals will be in the geriatric age-group (aged ≥65 years) in Hong Kong within the next 15 years. Unfortunately, improved longevity is not necessarily linked with improved health or healthcare. Ageing is an unavoidable process associated with many age-related diseases. For example, “immunosenescence”—the age-related dysregulation of the immune system—increases geriatric patients’ susceptibilities to a myriad of immune-mediated disorders (eg, infection, malignancy, and autoimmunity) and adverse reactions to medications. Adverse drug reactions (ADRs) are much more common in geriatric patients, such that they cause
significant morbidity and mortality, compared with younger patients.5,6 Geriatric patients are much more likely than younger patients to be hospitalised for ADRs.7 In particular, drug allergies (DAs) comprise approximately 6% to 10% of all ADRs and up to 10% of the resulting fatal reactions.6 Despite the severe consequences of genuine DAs, many patients mistakenly report non-immune-mediated ADRs as “allergies”. For example, almost 90% of patients with beta-lactam DA labels were confirmed not to be genuinely allergic in previous studies, although such incorrect DA labels were associated with a multitude of dire clinical consequences.5,6,7 To the best of our knowledge, although the prevalence of ADRs has been extensively reported in geriatric populations, there have been no adequate studies concerning the epidemiology or burden of DAs in geriatric patients.8 To address this lack of information, we performed a prospective analysis of the prevalence and outcomes of geriatric patients with DA labels in a cohort of hospitalised patients in Hong Kong.

Methods

All patients admitted to the acute general medical wards of Queen Mary Hospital from 1 July 2018 to 31 December 2018 were recruited for this study. The Queen Mary Hospital is the only public hospital in the Hong Kong West Cluster, which serves a population of 0.5 million and provides acute medical admissions through its Accident and Emergency Department. After admission, patients may be transferred to other convalescent or rehabilitation units of the Hong Kong West Cluster for further management if deemed unfit for direct discharge from the hospital. Patient age and sex were recorded, as was the presence of DA labels. All patients with DA labels were then followed until discharge; clinical data were anonymously extracted for analyses. Extracted clinical data included patient age and sex, presence and details of DA labels, length of stay (from the day of admission to the day of discharge [including stay at convalescent or rehabilitation hospitals] or death), and discharge outcomes (direct discharge, transfer to another hospital, or death). Details of DA labels were reviewed to ensure that the reported manifestations were consistent with the presence of clinical allergies (ie, immune-mediated hypersensitivity reactions). Manifestations suggestive of other non-immune-mediated ADRs were excluded.

The DA labels were categorised in accordance with the British National Formulary classifications (if available): beta-lactam antibiotics (5.1.1 Penicillins and 5.1.2 Cephalosporins and other beta-lactams), non-beta-lactam antibiotics (5.1 Antibacterial drugs, other than 5.1.1 and 5.1.2), non-steroidal anti-inflammatory drugs (10.1.1 NSAIDs), cardiovascular system (CVS) medications (2 CVS), intravenous contrast media, allopurinol, opioid analgesics (4.7.2 Opioid analgesics), non-opioid analgesics (4.7.1. Non-opioid analgesics and compound prep), antihistamines (3.4.1 Antihistamines), antifungals (5.2 Antifungal drugs), or others. Patients were categorised into either geriatric (aged ≥65 years) or non-geriatric (aged <65 years) groups. Demographic characteristics, clinical outcomes, and prevalences of DA labels were compared between groups.

The Chi squared test and independent samples t tests were respectively used to compare categorical and continuous variables between groups in univariate analysis. A P value of <0.05 was considered statistically significant for the multivariate analysis. IBM SPSS Statistics for Windows (version 20.0; IBM Corp, Armonk [NY, United States) was used for all analyses. The study protocol was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.

Results

There were 4361 admissions involving 3641 patients during the 6-month study period. The male-to-female ratio was 1:1.2. In total, 2522 patients (69.3%) were included in the geriatric group, with mean age 71.56±17.3 years.

In total, 492 patients (13.5%) had DA labels, consisting of 151 non-geriatric patients (30.7%) and 341 geriatric patients (69.3%) [Fig 1].

The overall prevalence of DA labels did not
significantly differ between geriatric and non-geriatric patients (13.5% [341/2522] vs 13.5% [151/1119], P=0.976) [Table]. The absolute and proportional prevalences of the top 10 categories of DA labels (in descending order) for geriatric and non-geriatric patients are shown in Figures 2 and 3, respectively.

The majority of patients with DA labels were aged ≥65 years (69.3%, 341/492). The male-to-female ratio did not significantly differ between geriatric and non-geriatric groups. Significantly more patients in the geriatric group had DA labels to CVS drugs (15.5% vs 4.6%, P=0.001), while the proportions of other DA labels were similar between the two groups. Patients in the geriatric group had a significantly lower rate of direct discharge from the hospital (73.0% vs 88.1%, P<0.001). The absolute mortality rate tended to be higher among patients in the geriatric group, but this difference was not statistically significant (10.3% vs 6.0%, P=0.123).

Discussion

Although the prevalence and consequences of overall ADRs have been extensively investigated, this is the first study to specifically examine the epidemiology and outcomes of geriatric patients with DA labels. In our cohort, 13.5% of all hospitalised geriatric patients had DA labels; the leading causes of DA labels were comparable between geriatric and non-geriatric patients. Notably, there were significantly more labelled DAs to CVS medications and significantly more adverse clinical outcomes in geriatric patients.

Adverse drug reactions are defined as any “appreciably harmful or unpleasant reaction” to medications which can occur through various immunological or non-immunological mechanisms. Drug allergies or “hypersensitivity reactions” comprise type B (non-dose-related) ADRs, which result from specific immune-mediated responses to a medication. An important problem is that many non-immune-mediated ADRs are often

| TABLE. Demographic characteristics, clinical outcomes, and prevalences of drug allergy labels in geriatric and non-geriatric patients* |
|---------------------------------|---------------------|------------------|-------------------|--------|
| | All patients with DA label, n=492 | Geriatric (aged ≥65 years), n=341 | Non-geriatric (aged <65 years), n=151 | P value |
| Female sex | 308 (62.6%) | 222 (65.1%) | 86 (57.0%) | 0.085 |
| DA labels | | | | |
| Beta-lactam antibiotics | 178 (36.2%) | 131 (38.4%) | 47 (31.1%) | 0.121 |
| Non-beta-lactam antibiotics | 123 (25.0%) | 82 (24.0%) | 41 (27.2%) | 0.463 |
| NSAIDs | 83 (16.9%) | 56 (16.4%) | 27 (17.9%) | 0.690 |
| CVS drugs | 60 (12.2%) | 53 (15.5%) | 7 (4.6%) | 0.001 |
| IV contrast | 39 (7.9%) | 22 (6.5%) | 17 (11.3%) | 0.069 |
| Allopurinol | 19 (3.9%) | 14 (4.1%) | 5 (3.3%) | 0.673 |
| Opioids | 7 (1.4%) | 4 (1.2%) | 3 (2.0%) | 0.126 |
| Non-opioid analgesics | 6 (1.2%) | 5 (1.5%) | 1 (0.7%) | 0.454 |
| Antihistamines | 6 (1.2%) | 5 (1.5%) | 1 (0.7%) | 0.454 |
| Antifungals | 4 (0.8%) | 1 (0.3%) | 3 (2.0%) | 0.054 |
| Outcomes | | | | |
| Length of stay, days | 12.0 ± 19.9 | 11.46 ± 18.8 | 13.1 ± 22.1 | 0.204 |
| Recurrent admissions | 78 (15.9%) | 56 (16.4%) | 22 (14.6%) | 0.604 |
| Direct discharge from the hospital | 382 (77.6%) | 249 (73.0%) | 133 (88.1%) | <0.001 |
| Mortality | 44 (8.9%) | 35 (10.3%) | 9 (6.0%) | 0.123 |

Abbreviations: CVS = cardiovascular system; DA = drug allergy; IV = intravenous; NSAIDs = non-steroidal anti-inflammatory drugs

* Data are shown as No. (%) or mean ± standard deviation, unless otherwise specified
clinically misinterpreted or incorrectly recorded as “allergies”. Although the initial DA reactions may be immunological, genuine allergies may gradually wane and warrant re-evaluation. For example, the vast majority of patients with beta-lactam allergies lose skin testing sensitivity over an interval of 10 years.\textsuperscript{15,16} Similarly, mild delayed (presumptively T-cell-mediated) reactions do not consistently recur.
upon re-exposure.\textsuperscript{17,18} Often, DA labels present in the medical records of geriatric patients have not undergone appropriate allergy testing to verify whether these labels remain accurate. Geriatric patients also have had more time and events to become sensitised or develop ADRs which may be interpreted as allergies; these labels may not be entirely correct for some patients. Overall, our study confirms the presence of the high burden of DA labels in geriatric patients and corresponding worse clinical outcomes (ie, significantly lower rate of direct discharge from the hospital) compared with non-geriatric patients. This highlights the urgent need to expand the availability of allergy testing for this vulnerable population.\textsuperscript{19,20}

As expected, beta-lactam antibiotics constituted the leading cause of DA labels in both patient populations in our study (61.5\% [131/213] in the geriatric group and 53.4\% [47/88] in the non-geriatric group). In Hong Kong, the prevalence of reported beta-lactam antibiotic allergy is approximately 2\% with a cumulative incidence approaching 10 per 100,000 population.\textsuperscript{21} Beta-lactam DA labels are known to have clinically significant consequences including the use of broad-spectrum antibiotics, enhanced microbial resistance, greater number of \textit{Clostridium difficile} infections, and expansions of multidrug-resistant organisms.\textsuperscript{19–11} In Hong Kong, Chen et al\textsuperscript{22} found that the prevalence of methicillin-resistant \textit{Staphylococcus aureus} was 30.1\% among older adults living in residential care homes. The presence of DA labels greatly restricts the repertoire of first-line antibiotics for such patients. Beta-lactams remain the most effective first-line treatment for many bacterial infections including methicillin-sensitive \textit{Staphylococcus aureus}; in agreement with our findings, the unnecessary use of alternatives leads to worse patient outcomes, especially in the vulnerable geriatric population.

Furthermore, we observed a significantly greater proportion of reported DAs to CVS drugs among geriatric patients. We postulate that this is related to the substantially greater burden of CVS diseases and exposure to CVS drugs in geriatric patients, compared with other conditions.\textsuperscript{23,24} As previously mentioned, although greater exposure to CVS drugs theoretically increases the risk of genuine DAs, “allergy” labels could be the result of incorrectly interpreted ADRs. For example, the incidences of angiotensin-converting enzyme inhibitor treatment–related cough and angioedema (non-immune-mediated ADRs) increase with age.\textsuperscript{25} Regardless of their accuracy, this greater proportion of DA labels to CVS drugs is likely to further restrict therapeutic options and elicit CVS complications in geriatric patients. The accuracies of these labels and their specific effects on CVS complications warrant dedicated studies in the future.

This study had some important limitations. First, a higher rate of other adverse clinical outcomes (such as recurrent admissions and mortality) was evident among patients in the geriatric group, although this was not statistically significant. This trend may have constituted a type II statistical analysis error due to inadequate sampling and observational design. Second, we only analysed geriatric and non-geriatric patients with DA labels, although geriatric patients may have worse clinical outcomes regardless of DA status. We were also unable to analyse individual DAs or manifestations within the CVS subgroup. Nonetheless, our findings highlight the vulnerability of this specific geriatric population and emphasise the need for future prospective studies. Third, although all DAs were recorded only after confirmation by the patients’ attending doctors and reported manifestations were screened by an allergist during data collection, we were unable to ascertain the accuracy of the DA labels. Comprehensive evaluations of suspected DAs often require allergological confirmation with skin and/or drug provocation tests, which is especially difficult in frail older adults. A follow-up study to identify the impacts of genuine allergies and incorrectly interpreted adverse clinical outcomes is currently in progress. Lastly, the results of our study were from a single-centre cohort of hospitalised patients and allergy records may have been influenced by local physician practices. Additional multicentre studies, including patients in the ambulatory setting, are needed to corroborate the external validity of our findings.

To the best of our knowledge, this is the first report concerning the epidemiology and outcomes of geriatric patients with DA labels. More than 13\% of hospitalised geriatric patients had DA labels; the leading causes of reported DAs in these patients were similar to those of non-geriatric patients in the same hospital. We also observed significantly more reported DAs to CVS drugs, as well as worse clinical outcomes (ie, more frequent transfer to convalescent or rehabilitation facilities) among patients in the geriatric group. Additional dedicated studies are required to confirm the burden and accuracy of DA labels among the already-vulnerable geriatric population.

\section*{Author contributions}

\textbf{Concept or design: PH Li.}

\textbf{Acquisition of data: PH Li.}

\textbf{Analysis or interpretation of data: PH Li, HY Chung.}

\textbf{Drafting of the manuscript: PH Li, CS Lau.}

\textbf{Critical revision of the manuscript for important intellectual content: All authors.}

All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
**Conflicts of interest**
All authors have disclosed no conflicts of interest.

**Funding/support**
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Ethics approval**
Ethical approval was obtained from HKU/ HKW Institutional Review Board of The University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB), Ref UW 18-669.

**References**


